- The stock price of Novan Inc (NASDAQ: NOVN) increased by 62.39% yesterday. These are the details.
The stock price of Novan Inc (NASDAQ: NOVN) increased by 62.39% yesterday as it went from a previous close of $9.04 to $14.68. Investors responded positively to the company announcing the topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum — which is a common and contagious skin infection caused by the molluscipoxvirus, affecting approximately 6 million people in the U.S. annually with the greatest incidence in children aged one to 14 years.
B-SIMPLE4 is a multi-center, double-blind, randomized, vehicle-controlled study that had exceeded its enrollment target by randomizing 891 patients (1:1 randomization) in the study, across 55 clinical sites. And patients were treated for up to 12 weeks with a follow-up visit at Week 24.
The primary endpoint for the study is the proportion of patients with complete clearance of all treatable molluscum lesions at Week 12 (Intent-to-Treat or ITT population where the analysis assumes that patients with missing data at Week 12 are considered treatment failures).
This a summary of the primary and secondary endpoints:
Consistent with results from Novan’s Phase 2 and earlier Phase 3 studies, SB206 was found to be safe and well-tolerated. No treatment-related serious adverse events (TEAE) were reported.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.